Despite the introduction of new anti-seizure medications in recent years, approximately one-
third of the epileptic population continues to experience seizures. Recently, the anti-obesity …

Introduction Dravet syndrome is a severe early infancy-onset developmental and epileptic
encephalopathy. Patients have drug-resistant seizures, as well as significant co-morbidities …

Background Novel treatments are needed to control refractory status epilepticus (SE). This
study aimed to assess the potential effectiveness of fenfluramine (FFA) as an acute …

Developmental and epileptic encephalopathies (DEEs) are characterized by
pharmacoresistant seizures and developmental delay. Patients with DEEs experience …

The effect of fenfluramine and norfenfluramine enantiomers in rodent seizure models and
their correlation with the pharmacokinetics of d‐and l‐fenfluramine in rats have been …

Objective Sudden unexpected death in epilepsy (SUDEP) is an underestimated
complication of epilepsy. Previous studies have demonstrated that enhancement of …

Objective Given its key homeostatic role affecting mitochondria, ionotropic and metabotropic
receptors, and voltage‐gated ion channels, sigma‐1 receptor (Sig1R) represents an …

In the landscape of paediatric epilepsy treatment, over 20 anti-seizure medications (ASMs)
have gained approval from Drug Regulatory Agencies, each delineating clear indications …

Both clinical and animal studies demonstrated that seizure-induced respiratory arrest (S-
IRA) contributes importantly to sudden unexpected death in epilepsy (SUDEP). It has been …

ABSTRACT Introduction Developmental epileptic encephalopathies (DEEs) pose significant
challenges due to their refractory nature and limited treatment options. Despite …